Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019-Associated Hospitalization Prevention : A Population-based Cohort Study in the Province of Quebec, Canada
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Nirmatrelvir/ritonavir has shown to reduce COVID-19 hospitalization and death before Omicron, but updated real-world evidence studies are needed. This study aimed to assess whether nirmatrelvir/ritonavir reduces the risk of COVID-19-associated hospitalization among high-risk outpatients.
METHODS: A retrospective cohort study of outpatients with SARS-CoV-2 between March 15 and 15 October 2022, using data from the Quebec clinico-administrative databases. Outpatients treated with nirmatrelvir/ritonavir were compared with infected ones not receiving nirmatrelvir/ritonavir using propensity-score matching. Relative risk (RR) of COVID-19-associated hospitalization within 30 days was assessed using a Poisson regression.
RESULTS: A total of 8402 treated outpatients were matched to controls. Regardless of vaccination status, nirmatrelvir/ritonavir treatment was associated with a 69% reduced RR of hospitalization (RR: .31; 95% CI: .28; .36; number needed to treat [NNT] = 13). The effect was more pronounced in outpatients with incomplete primary vaccination (RR: .04; 95% CI: .03; .06; NNT = 8), while no benefit was found in those with a complete primary vaccination (RR: .93; 95% CI: .78; 1.08). Subgroups analysis among high-risk outpatients with a complete primary vaccination showed that nirmatrelvir/ritonavir treatment was associated with a significant decrease in the RR of hospitalization in severely immunocompromised outpatients (RR: .66; 95% CI: .50; .89; NNT = 16) and in high-risk outpatients aged ≥70 years (RR: .50; 95% CI: .34; .74; NNT = 10) when the last dose of the vaccine was received at least 6 months ago.
CONCLUSIONS: Nirmatrelvir/ritonavir reduces the risk of COVID-19-associated hospitalization among incompletely vaccinated high-risk outpatients and among some subgroups of completely vaccinated high-risk outpatients.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
---|---|
Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 77(2023), 6 vom: 18. Sept., Seite 805-815 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kaboré, Jean-Luc [VerfasserIn] |
---|
Links: |
---|
Themen: |
7R9A5P7H32 |
---|
Anmerkungen: |
Date Completed 20.09.2023 Date Revised 20.09.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1093/cid/ciad287 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM356528863 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM356528863 | ||
003 | DE-627 | ||
005 | 20231226070646.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/cid/ciad287 |2 doi | |
028 | 5 | 2 | |a pubmed24n1188.xml |
035 | |a (DE-627)NLM356528863 | ||
035 | |a (NLM)37149726 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kaboré, Jean-Luc |e verfasserin |4 aut | |
245 | 1 | 0 | |a Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019-Associated Hospitalization Prevention |b A Population-based Cohort Study in the Province of Quebec, Canada |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 20.09.2023 | ||
500 | |a Date Revised 20.09.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
520 | |a BACKGROUND: Nirmatrelvir/ritonavir has shown to reduce COVID-19 hospitalization and death before Omicron, but updated real-world evidence studies are needed. This study aimed to assess whether nirmatrelvir/ritonavir reduces the risk of COVID-19-associated hospitalization among high-risk outpatients | ||
520 | |a METHODS: A retrospective cohort study of outpatients with SARS-CoV-2 between March 15 and 15 October 2022, using data from the Quebec clinico-administrative databases. Outpatients treated with nirmatrelvir/ritonavir were compared with infected ones not receiving nirmatrelvir/ritonavir using propensity-score matching. Relative risk (RR) of COVID-19-associated hospitalization within 30 days was assessed using a Poisson regression | ||
520 | |a RESULTS: A total of 8402 treated outpatients were matched to controls. Regardless of vaccination status, nirmatrelvir/ritonavir treatment was associated with a 69% reduced RR of hospitalization (RR: .31; 95% CI: .28; .36; number needed to treat [NNT] = 13). The effect was more pronounced in outpatients with incomplete primary vaccination (RR: .04; 95% CI: .03; .06; NNT = 8), while no benefit was found in those with a complete primary vaccination (RR: .93; 95% CI: .78; 1.08). Subgroups analysis among high-risk outpatients with a complete primary vaccination showed that nirmatrelvir/ritonavir treatment was associated with a significant decrease in the RR of hospitalization in severely immunocompromised outpatients (RR: .66; 95% CI: .50; .89; NNT = 16) and in high-risk outpatients aged ≥70 years (RR: .50; 95% CI: .34; .74; NNT = 10) when the last dose of the vaccine was received at least 6 months ago | ||
520 | |a CONCLUSIONS: Nirmatrelvir/ritonavir reduces the risk of COVID-19-associated hospitalization among incompletely vaccinated high-risk outpatients and among some subgroups of completely vaccinated high-risk outpatients | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a effectiveness | |
650 | 4 | |a nirmatrelvir | |
650 | 4 | |a ritonavir | |
650 | 7 | |a nirmatrelvir |2 NLM | |
650 | 7 | |a 7R9A5P7H32 |2 NLM | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
700 | 1 | |a Laffont, Benoît |e verfasserin |4 aut | |
700 | 1 | |a Diop, Mamadou |e verfasserin |4 aut | |
700 | 1 | |a Tardif, Melanie R |e verfasserin |4 aut | |
700 | 1 | |a Turgeon, Alexis F |e verfasserin |4 aut | |
700 | 1 | |a Dumaresq, Jeannot |e verfasserin |4 aut | |
700 | 1 | |a Luong, Me-Linh |e verfasserin |4 aut | |
700 | 1 | |a Cauchon, Michel |e verfasserin |4 aut | |
700 | 1 | |a Chapdelaine, Hugo |e verfasserin |4 aut | |
700 | 1 | |a Claveau, David |e verfasserin |4 aut | |
700 | 1 | |a Brosseau, Marc |e verfasserin |4 aut | |
700 | 1 | |a Haddad, Elie |e verfasserin |4 aut | |
700 | 1 | |a Benigeri, Mike |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 77(2023), 6 vom: 18. Sept., Seite 805-815 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
773 | 1 | 8 | |g volume:77 |g year:2023 |g number:6 |g day:18 |g month:09 |g pages:805-815 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad287 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 77 |j 2023 |e 6 |b 18 |c 09 |h 805-815 |